Bank Loans, MLPs Be...
Health Care: Drugs
Synthetic Biologics Inc (SYN: AMEX)
$1.41 -0.01 | -0.70%
05/22/13 - 02:45 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 9.95M | 6.68M | 2.65M | 2.72M |
| Receivables | 0.00 | 405.00K | 338.51K | 30.57K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 39.00K | 343.42K | 8.97K |
| Total Current Assets | 12.46M | 7.12M | 3.33M | 2.75M |
| Property, Plant & Equipment, Gross | 465.00K | 695.00K | 1.65M | 2.04M |
| Accumulated Depreciation & Depletion | 242.00K | 372.00K | 1.14M | 985.96K |
| Property, Plant & Equipment, Net | 223.00K | 323.00K | 511.14K | 1.05M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 737.00K | 31.00K | 90.85K | 90.85K |
| Total Non-Current Assets | 960.00K | 354.00K | 780.22K | 1.32M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 13.42M | 7.48M | 4.11M | 4.08M |
| Accounts Payable | 395.00K | 388.00K | 265.72K | 400.48K |
| Short Term Debt | 0.00 | 0.00 | 24.40K | 17.01K |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 395.00K | 417.00K | 500.15K | 425.64K |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 32.34K | 93.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 32.34K | 105.79K |
| Total Liabilities | 395.00K | 417.00K | 532.48K | 531.43K |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 13.03M | 7.06M | 3.58M | 3.54M |
| Common Par | 44.00K | 31.00K | 23.34K | 21.45K |
| Additional Paid In Capital | 81.92M | 58.90M | 47.28M | 45.55M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -68.94M | -51.87M | -43.72M | -42.01M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | -17.10K |
| Total Capitalization | 13.03M | 7.06M | 3.58M | 3.54M |
| Total Equity | 13.03M | 7.06M | 3.58M | 3.54M |
| Total Liabilities & Stock Equity | 13.42M | 7.48M | 4.11M | 4.08M |
| Total Common Shares Outstanding | 44.36M | 31.29M | 23.34M | 21.45M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 81.48K | 81.48K | 81.48K | 81.51K |
| Basic Weighted Shares Outstanding | 34.90M | 27.71M | 22.39M | 21.32M |
| Diluted Weighted Shares Outstanding | 34.90M | 27.71M | 22.39M | 21.32M |
| Number of Employees | 8 | 7 | 13 | 10 |
| Number of Part-Time Employees | 6 | 1 | 0 | 0 |
Portfolios with SYN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest SYN Headlines from TheStreet
- 3 Biotech Stocks Under $5 Moving Higher 02.07.13 | 02:02 pm
- 5 Stocks Poised for Breakouts 07.13.12 | 12:07 pm
- Synovus To Raise $350M in Stock Offer 09.14.09 | 11:09 pm
- Regions' Profit Stung by Fla. Real Estate 07.22.08 | 11:07 am
- Stock Upgrades, Downgrades from TheStreet.com Ratings 11.21.07 | 01:11 pm
- Cramer's 'Mad Money Lightning Round': Best BuyBuyBuy 10.01.07 | 07:10 pm
- Neurocrine Says Sleeping Pill Data Are Good 11.14.02 | 09:11 am
Press Releases for SYN
- Synthetic Biologics To Present At The 2nd Annual Marcum LLP MicroCap Conference - PR Newswire 05.21.13 | 07:05 am
- Synthetic Biologics Reiterates That The Infectious Disease Collaboration With Intrexon Remains In Effect - PR Newswire 04.19.13 | 07:04 pm
- Synthetic Biologics Announces Issuance Of U.S. Patent Covering Combination Of Estriol And Copaxone® For Multiple Sclerosis - PR Newswire 04.04.13 | 01:04 pm
- Synthetic Biologics To Present At The 25th Annual ROTH Conference - PR Newswire 03.12.13 | 07:03 am
- Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics' Scientific Advisory Board - PR Newswire 02.26.13 | 07:02 am
- Synthetic Biologics Reports That Flupirtine Sublicensee, Meda AB, To Initiate Phase II Fibromyalgia Clinical Trial In U.S. - PR Newswire 02.22.13 | 07:02 am
- Synthetic Biologics To Present At The 2013 BIO CEO & Investor Conference - PR Newswire 02.05.13 | 07:02 am
- Synthetic Biologics To Present At OneMedForum San Francisco 2013 - PR Newswire 01.07.13 | 07:01 am
- Synthetic Biologics And Intrexon Corporation Initiate Development Of Monoclonal Antibodies For Whooping Cough (Pertussis) - PR Newswire 12.20.12 | 04:12 pm
- Synthetic Biologics Closes Deal For Acquisition Of C. Difficile Infectious Disease Program - PR Newswire 12.03.12 | 02:12 pm
Partner Headlines for SYN
